Skip to main content
Top
Published in: Drugs & Aging 11/2006

01-11-2006 | From the World Literature

Gerontology Forum

An Update on the Literature

Published in: Drugs & Aging | Issue 11/2006

Login to get access

Excerpt

  • Abstract
  • 1. Menthol May Improve Swallowing Reflex Times in Elderly Patients with Dysphagia
  • 2. Cell Culture-Derived Influenza Virus Vaccine has Demonstrated Immunogenicity and Tolerability Equivalent to that of a Standard Vaccine
  • 3. Is Varicella Zoster Vaccine Worth the Cost?
  • 4. Abuse-Deterrent, Extended-Release Opioid Capsule Provides Effective Pain Relief for Patients with Osteoarthritis
  • 5. No Major Anti-Aging Benefits Associated with Prasterone (Dehydroepiandrosterone; DHEA) or Testosterone
  • 6. Conjugated Estrogens Do Not Increase the Risk of Breast Cancer in Postmenopausal Women with Prior Hysterectomy, and May Even Be Protective in Some Women
  • 7. Bisphosphonates for Fractures: Persistence Provides Protection
  • 8. Once-Monthly Ibandronic Acid Along with Patient Support is Associated with Higher Treatment Persistence than Once-Weekly Alendronic Acid
  • 9. Warfarin Use and Age ≥ 70 Years Appear to be Associated with Increased Intracranial Haemorrhage Risk and Mortality in Patients with Head Trauma
  • 10. Cognitive Effects of Insulin Lead to Good Ideas for Treatment
  • 11. Fruit and Vegetable Intake Decreases Risk of Alzheimer’s Disease
  • 12. Pumping Problem Possible in Pergolide-Treated Parkinson’s Disease Patients
  • 13. CERE 120 Reduces Symptoms of Parkinson’s Disease and is Well Tolerated
  • 14. Caffeine Appears to Increase the Rate of Onset of Levodopa Benefits for Patients with Idiopathic Parkinson’s Disease
  • 15. Deep-Brain Stimulation Plus Medications Appears to be More Effective than Medical Therapy Alone in Patients with Parkinson’s Disease
  • 16. Topical Rotigotine Effectively Improves Symptoms in Patients with Moderate-to-Severe Restless Legs Syndrome
  • 17. Pramipexole for Restless Legs Syndrome Results in Quality of Life Improvements that Remain at 1 Year
Footnotes
1
Novartis; preregistration in Europe and phase I/II in the US.
 
2
Costs (2006 values) were for vaccinations, outpatient visits, antivirals, hospitalisation, postherpetic neuralgia management and lost work productivity. Costs and benefits were discounted at 3% per annum.
 
3
This study was supported by GlaxoSmithKline, UK and F. Hoff-mann-La Roche, Switzerland.
 
4
This study was supported by Roche Products.
 
5
Patients without Parkinson’s disease referred for echocardiography but with no known valvulopathy.
 
6
Ceregene; phase I for Parkinson’s disease in the US.
 
7
During which patients received rotigotine 2.25 mg/day patches or placebo.
 
8
One author was affiliated with Boehringer Ingelheim Pharma GmbH.
 
Literature
go back to reference Ebihara T, Ebihara S, Watando A, et al. Effects of menthol on the triggering of the swallowing reflex in elderly patients with dysphagia. Br J Clin Pharmacol 2006 Sep; 62(3): 369–71PubMedCrossRef Ebihara T, Ebihara S, Watando A, et al. Effects of menthol on the triggering of the swallowing reflex in elderly patients with dysphagia. Br J Clin Pharmacol 2006 Sep; 62(3): 369–71PubMedCrossRef
go back to reference Novartis. Pivotal phase III trial results show Novartis cell culture-derived influenza vaccine well tolerated and efficacious [media release]. 2006 Oct 19. Novartis [online]. Available from URL: http://www.novartis.com [Accessed 2006 Oct 28] Novartis. Pivotal phase III trial results show Novartis cell culture-derived influenza vaccine well tolerated and efficacious [media release]. 2006 Oct 19. Novartis [online]. Available from URL: http://​www.​novartis.​com [Accessed 2006 Oct 28]
go back to reference Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2005 Sep 5; 145(5): 317–25 Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2005 Sep 5; 145(5): 317–25
go back to reference Alpharma Inc. Alpharma announces positive results from a phase II safety, efficacy and pharmacokinetic study of its abuse-deterrent, extended-release opioid [media release]. 2006 Sep 28. Alpharma Inc. [online]. Available from URL: http://www.alpharma.com [Accessed 2006 Oct 7] Alpharma Inc. Alpharma announces positive results from a phase II safety, efficacy and pharmacokinetic study of its abuse-deterrent, extended-release opioid [media release]. 2006 Sep 28. Alpharma Inc. [online]. Available from URL: http://​www.​alpharma.​com [Accessed 2006 Oct 7]
go back to reference Sreekumaran Nair K, Rizza RA, O’Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006 Oct 19; 355(16): 1647–59PubMedCrossRef Sreekumaran Nair K, Rizza RA, O’Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006 Oct 19; 355(16): 1647–59PubMedCrossRef
go back to reference Pines A, Sturdee DW, Birkhäuser M, International Menopause Society. WHI and breast cancer: a response to a recent publication from the WHI. Climacteric 2006 Aug; 9(4): 244PubMedCrossRef Pines A, Sturdee DW, Birkhäuser M, International Menopause Society. WHI and breast cancer: a response to a recent publication from the WHI. Climacteric 2006 Aug; 9(4): 244PubMedCrossRef
go back to reference van den Boogaard CHA, Breekveldt-Postma NS, Borggreve SE, et al. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 2006 Sep; 22(9): 1757–64PubMedCrossRef van den Boogaard CHA, Breekveldt-Postma NS, Borggreve SE, et al. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 2006 Sep; 22(9): 1757–64PubMedCrossRef
go back to reference Cooper A, Drake J, Brankin E, PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006 Aug; 60(8): 896–905PubMedCrossRef Cooper A, Drake J, Brankin E, PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006 Aug; 60(8): 896–905PubMedCrossRef
go back to reference Franko J, Kish KJ, O’Connell BG, et al. Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma. J Trauma 2006 Jul; 61(1): 107–10PubMedCrossRef Franko J, Kish KJ, O’Connell BG, et al. Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma. J Trauma 2006 Jul; 61(1): 107–10PubMedCrossRef
go back to reference Dai Q, Borenstein AR, Wu Y, et al. Fruit and vegetable juices and Alzheimer’s disease: the Kame Project. Am J Med 2006 Sep; 119(9): 751–9PubMedCrossRef Dai Q, Borenstein AR, Wu Y, et al. Fruit and vegetable juices and Alzheimer’s disease: the Kame Project. Am J Med 2006 Sep; 119(9): 751–9PubMedCrossRef
go back to reference Dupuy D, Lesbre JP, Andréjak M, et al. Valvular heart disease in patients with Parkinson’s disease treated with pergolide. Drug Saf 2006; 29(10): 1005CrossRef Dupuy D, Lesbre JP, Andréjak M, et al. Valvular heart disease in patients with Parkinson’s disease treated with pergolide. Drug Saf 2006; 29(10): 1005CrossRef
go back to reference Ceregene Inc. Ceregene announces promising phase 1 results from gene therapy trial for Parkinson’s disease [media release]. 2006 Oct 10. Ceregene Inc. [online]. Available from URL: http://www.ceregene.com [Accessed 2006 Oct 21] Ceregene Inc. Ceregene announces promising phase 1 results from gene therapy trial for Parkinson’s disease [media release]. 2006 Oct 10. Ceregene Inc. [online]. Available from URL: http://​www.​ceregene.​com [Accessed 2006 Oct 21]
go back to reference Deleu D, Jacob P, Chand P, et al. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease. Neurology 2006 Sep 12; 67(5): 897–9PubMedCrossRef Deleu D, Jacob P, Chand P, et al. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease. Neurology 2006 Sep 12; 67(5): 897–9PubMedCrossRef
go back to reference Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 2006 Aug 31; 355(9): 896–908PubMedCrossRef Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 2006 Aug 31; 355(9): 896–908PubMedCrossRef
go back to reference Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. One-year persistence of improved quality of life during pramipexole therapy of restless legs syndrome [abtract no. P2127]. 10th Congress of the European Federation of Neurological Societies; 2006 Sep 2; Glasgow [online]. Available from URL: http://www.kenes.com/efns2006 [Accessed 2006 Oct 14] Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. One-year persistence of improved quality of life during pramipexole therapy of restless legs syndrome [abtract no. P2127]. 10th Congress of the European Federation of Neurological Societies; 2006 Sep 2; Glasgow [online]. Available from URL: http://​www.​kenes.​com/​efns2006 [Accessed 2006 Oct 14]
Metadata
Title
Gerontology Forum
An Update on the Literature
Publication date
01-11-2006
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 11/2006
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200623110-00007

Other articles of this Issue 11/2006

Drugs & Aging 11/2006 Go to the issue

Review Article

HIV and Aging

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.